Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. ImmunoGen, Inc.
  6. Summary
    IMGN   US45253H1014

IMMUNOGEN, INC.

(IMGN)
  Report
Delayed Quote. Delayed Nasdaq - 05/27 04:00:00 pm
3.84 USD   +4.35%
05/27SECTOR UPDATE : Health Care Stocks End Higher
MT
05/27SECTOR UPDATE : Health Care
MT
05/27SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/23/2022 05/24/2022 05/25/2022 05/26/2022 05/27/2022 Date
3.57(c) 3.54(c) 3.47(c) 3.68(c) 3.84(c) Last
4 688 242 3 378 313 3 257 168 4 417 888 3 169 812 Volume
-0.28% -0.84% -1.98% +6.05% +4.35% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 85,7 M - -
Net income 2022 -206 M - -
Net cash position 2022 243 M - -
P/E ratio 2022 -4,55x
Yield 2022 -
Sales 2023 136 M - -
Net income 2023 -196 M - -
Net cash position 2023 180 M - -
P/E ratio 2023 -5,06x
Yield 2023 -
Capitalization 847 M 847 M -
EV / Sales 2022 7,05x
EV / Sales 2023 4,90x
Nbr of Employees 106
Free-Float 99,6%
More Financials
Company
ImmunoGen, Inc. is a clinical-stage biotechnology company focused on developing the antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/08 | 12:20pmPresentation
More about the company
Ratings of ImmunoGen, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about IMMUNOGEN, INC.
05/27SECTOR UPDATE : Health Care Stocks End Higher
MT
05/27SECTOR UPDATE : Health Care
MT
05/27SECTOR UPDATE : Health Care Stocks Gain Premarket Friday
MT
05/26ImmunoGen Says More Than 70% of Ovarian Cancer Patients Showed Tumor Reduction in Mirve..
MT
05/26ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Sora..
BU
05/26ImmunoGen Presents Additional Efficacy and Safety Analyses Evaluating Mirvetuximab Sora..
CI
05/25ImmunoGen Announces Webcasts of Presentations at Upcoming Conferences
BU
05/24TRANSCRIPT : ImmunoGen, Inc. Presents at H.C. Wainwright Global Investment Conference 2022..
CI
05/23SECTOR UPDATE : Health Care Stocks Mixed Premarket Monday
MT
05/23IMMUNOGEN : Announces Acceptance of Biologics License Application for Mirvetuximab Soravta..
PU
05/23IMMUNOGEN, INC. : Regulation FD Disclosure, Other Events, Financial Statements and Exhibit..
AQ
05/23ImmunoGen Says FDA Approves Biologics License Application of Mirvetuximab Soravtansine ..
MT
05/23ImmunoGen Announces Acceptance of Biologics License Application for Mirvetuximab Soravt..
BU
05/23Immunogen Announces Acceptance of Biologics License Application for Mirvetuximab Soravt..
CI
05/23ImmunoGen Gets FDA Priority Review of Mirvetuximab Soravtansine in Ovarian Cancer
DJ
More news
News in other languages on IMMUNOGEN, INC.
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé terminent en hausse
05/27MISE À JOUR SECTORIELLE : Les actions du secteur de la santé progressent vendredi avant le..
05/26ImmunoGen affirme que plus de 70 % des patientes atteintes d'un cancer ovarien ont prés..
05/26ImmunoGen présente des analyses supplémentaires d'efficacité et de sécurité évaluant le..
05/23MISE À JOUR SECTORIELLE : Les actions du secteur de la santé sont mitigées lundi avant le ..
More news
Analyst Recommendations on IMMUNOGEN, INC.
More recommendations
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | MarketScreener
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 3,84 $
Average target price 11,50 $
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Mark Joseph Enyedy President, Chief Executive Officer & Director
Susan Altschuller Chief Financial Officer & Senior Vice President
Stephen C. McCluski Chairman
Anna Berkenblit Chief Medical Officer & Senior Vice President
Thomas Ryll Vice President-Process & Analytical Development
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOGEN, INC.-48.25%847
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
SEAGEN INC.-8.54%26 026
ICON PUBLIC LIMITED COMPANY-26.61%18 478